Trial Failure of Antibody Targeting Alpha-synuclein Detailed

Treatment with prasinezumab, a monoclonal antibody designed to break up toxic alpha-synuclein aggregates, failed to slow the progression of Parkinson’s disease in a Phase 2 clinical trial. “In this placebo-controlled trial, treatment with prasinezumab, a humanized monoclonal antibody targeting aggregated [alpha]-synuclein, had no meaningful effect on global clinical or…

Nanobody Has Potential to Combat Alpha-synuclein Clumps

A miniature antibody-like molecule called a nanobody effectively broke up toxic alpha-synuclein aggregates that are characteristic of Parkinson’s disease, and prevented the spread of these aggregates in the brains of mice in a disease model. The novel construct was described in the journal Nature Communications, in the study, “…

Kynmobi Does Not Significantly Alter Heartbeat, Study Finds

Treatment with Kynmobi (apomorphine hydrochloride), an approved under-the-tongue therapy for “off” episodes in Parkinson’s disease, does not substantially alter heartbeat dynamics at approved doses, according to new clinical trial data. The study, “A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s…

Researchers Design New Approach to Help Medications Enter the Brain

Researchers have developed a new method of temporarily opening the selective blood-brain barrier (BBB) to allow therapeutic molecules greater access to the brain. Difficulties in developing molecules that can cross this barrier have long hindered the development of treatments for neurological diseases, like Parkinson’s disease. The technique could now…

Buntanetap Shows Efficacy, Supports Soon-to-open Phase 3 Study

Buntanetap, Annovis Bio’s investigational oral treatment for neurodegenerative diseases, was safe and showed effectiveness in people with early-stage Parkinson’s disease, a presentation of Phase 2 trial data showed, paving the way for Phase 3 testing in a larger patient group. The U.S. Food and Drug Administration recently gave the…

Parkinson’s Foundation Supports Training for Doctors, Nurses

The Parkinson’s Foundation invested $1.1 million in two fellowships programs aimed at giving neurologists and nurse practitioners more specialized and expert training in Parkinson’s disease (PD). Specifically, the investment supports the Institutional Movement Disorder (IMDS) Fellowship Program for neurologists and the newly opened Nurse Practitioner (NP) Fellowship in Movement Disorders.

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums